RANK Ligand

A transmembrane protein belonging to the tumor necrosis factor superfamily that specifically binds RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B and OSTEOPROTEGERIN. It plays an important role in regulating OSTEOCLAST differentiation and activation.

Also Known As:

CD254 Antigen; OPGL Protein; Osteoclast Differentiation Factor; Osteoprotegerin Ligand; RANKL Protein; Receptor Activator of Nuclear Factor-kappa B Ligand; Receptor Activator of Nuclear Factor-kappaB Ligand; TNF Superfamily, Member 11; TRANCE Protein; Tumor Necrosis Factor-Related Activation-Induced Cytokine; Antigen, CD254; Differentiation Factor, Osteoclast; Receptor Activator of Nuclear Factor kappa B Ligand; Receptor Activator of Nuclear Factor kappaB Ligand; Tumor Necrosis Factor Related Activation Induced Cytokine; Tumor Necrosis Factor Ligand Superfamily Member 11

Networked: 1055 relevant articles (20 outcomes, 110 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Terpos, Evangelos: 17 articles (11/2018 - 08/2003)
2.	Dougall, William C: 16 articles (11/2018 - 11/2002)
3.	Lewiecki, E Michael: 10 articles (11/2018 - 07/2006)
4.	Kostenuik, Paul J: 9 articles (01/2018 - 10/2005)
5.	Schwarz, Edward M: 8 articles (01/2021 - 03/2002)
6.	Ueland, Thor: 8 articles (06/2010 - 07/2002)
7.	Hofbauer, Lorenz C: 7 articles (01/2018 - 01/2002)
8.	Aukrust, Pål: 7 articles (06/2010 - 05/2005)
9.	Hofbauer, L C: 7 articles (01/2004 - 01/2000)
10.	Udagawa, Nobuyuki: 6 articles (01/2022 - 01/2002)

Related Diseases

1.	Neoplasm Metastasis (Metastasis) 01/01/2012 - "In preclinical studies, RANK Ligand inhibition has been shown to prevent the development of bone and some visceral metastases. " 05/01/2015 - "However, extensive metastasis was observed in functionalized scaffolds, and the highest levels for scaffolds that were in situ manipulated with receptor activator of nuclear factor kappa-B ligand (RANKL). " 02/01/2014 - "RANK ligand (RANKL), acting through its cognate receptor RANK, is a key factor for bone remodeling and metastasis by regulating the differentiation, survival and activation of osteoclasts. " 11/01/2013 - "[Inhibition of RANK ligand to treat bone metastases]." 10/01/2013 - "Receptor activator of nuclear factor-κB (RANK) and RANK ligand (RANKL) belong to a signal pathway highly implicated in the development of bone metastases. "
2.	Osteoporosis 01/01/2023 - "Here, we analysed CaP nanoparticles in a genetically modified medaka fish model, where osteoporosis-like lesions can be induced by transgenic expression of receptor activator of nuclear factor kappa-B ligand (Rankl). " 11/01/2021 - "Receptor activator of nuclear factor kappa-B ligand (RANKL) is one of the key factors regulating the maturation of osteoclasts and an important target for osteoporosis treatment. " 01/01/2020 - "The anti-Rank ligand and PTH analogs have no impact on cardiovascular risk and overall mortality in idiopathic osteoporosis. " 01/01/2020 - "A literature review and meta-analysis were conducted to address the impact of PTH analogs and anti-Rank ligand on cardiovascular events and overall mortality in individuals with idiopathic osteoporosis. " 01/01/2020 - "A literature review and meta-analysis were conducted to address the impact of PTH analogs and anti-Rank ligand on cardiovascular events and overall mortality in individuals with idiopathic osteoporosis; these treatments do not appear to have any effect. "
3.	Bone Resorption 01/01/2019 - "We found that ANTXR1 positively regulated the receptor activator of nuclear factor kappa B ligand (RANKL)-induced osteoclast differentiation and bone resorption with no effects on osteoblast differentiation by performing gain- and loss-of-function studies. " 12/01/2023 - "The IgSF11-expressing cells in OA subchondral bone were found to be involved in osteoclast maturation and bone resorption and colocalized with receptor-activator of nuclear-factor κ-B (RANK), the key osteoclast differentiation factor. " 10/05/2023 - "Receptor activator of nuclear factor kappa-B ligand (RANKL) is exhibited from osteoblastic cells that gathered osteoclasts to bone sites for bone resorption, accelerating bone loss. " 10/01/2023 - "It targets RANKL, the receptor activator of NF-κB (RANK) ligand, blocking RANKL-RANK interaction and leading to rapid osteoclast-mediated bone resorption inhibition. " 08/23/2023 - "We showed that IBC dose-dependently suppressed receptor activator of nuclear factor kappa B ligand (RANKL)-induced osteoclastogenesis in bone marrow monocyte/macrophage (BMMs) and osteoclastic bone-resorption function without cytotoxicity at a dose of no more than 8 µmin vitro. "
4.	Neoplasms (Cancer) 08/01/2012 - "While previous studies showed that MPA induces receptor activator of nuclear factor kappa-B ligand (RANKL) expression in rodent mammary gland, MPA reduced levels of RANKL in human tumor xenografts. " 03/01/2002 - "Immunohistochemical study of receptor activator of nuclear factor kappa-B ligand (RANK-L) in human osteolytic bone tumors." 04/01/2023 - "Arising mostly in epiphysis of the long bones in young adults, the tumor is composed of mononuclear cells that are admixed with osteoclastic giant cells(OLGCs), which express RANK ligand and RANK respectively. " 01/01/2021 - "Importantly, RANKK240E transgenic CLL cells as well as CLL cells of independent murine and of human origin depend on microenvironmental RANK ligand (RANKL) for tumor cell survival. " 02/01/2019 - "Our previous results recently revealed that the receptor activator of NF-κB (RANK) ligand (RANKL), which is expressed by bone marrow stromal cells, contributes to anti-cancer drug resistance through the activation of various signaling molecules and suppression of Bim expression in RANK-expressing MM cells. "
5.	Prostatic Neoplasms (Prostate Cancer) 03/01/2016 - "Previous work into RANK and prostate cancer has focused on its interaction with the bone environment, particularly with regard to its receptor RANK ligand. " 01/01/2009 - "Expression of RANK-ligand in prostate cancer cell lines." 09/01/2011 - "A large randomized trial of denosumab, an antibody to RANK ligand, in prostate cancer has demonstrated prevention of bone loss and a reduction in fractures. " 03/01/2011 - "The purpose of this study was to investigate the influence of combined inhibition of receptor activator of nuclear factor kappa-B ligand (RANKL) and bone morphogenetic protein (BMP) activity in a mixed lytic/blastic prostate cancer lesion in bone. " 03/14/2017 - "In addition, we discuss the roles of interleukin-6 and receptor activator of nuclear factor kappa-B ligand in modulating prostate cancer progression. "

Related Drugs and Biologics

1.	Denosumab
2.	Monoclonal Antibodies
3.	Osteoprotegerin
4.	Zoledronic Acid (Zometa)
5.	Diphosphonates (Bisphosphonates)
6.	Receptor Activator of Nuclear Factor-kappa B (TRANCE-R)
7.	Parathyroid Hormone (Parathormone)
8.	Osteopontin
9.	Cathepsin K
10.	Estrogens (Estrogen)

Related Therapies and Procedures

1.	Therapeutics
2.	Ovariectomy (Oophorectomy)
3.	Ligation
4.	Hip Replacement Arthroplasty (Total Hip Replacement)
5.	Retreatment